Your browser doesn't support javascript.
Correlation of ACE2 with RAS components after Losartan treatment in light of COVID-19.
Zaheer, Javeria; Kim, Hyeongi; Kim, Jin Su.
  • Zaheer J; Division of RI Application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Gil, Gongneung-Dong, Nowon-Gu, Seoul, 01812, Korea.
  • Kim H; Radiological and Medico-Oncological Sciences, University of Science and Technology (UST), Seoul, 01812, Korea.
  • Kim JS; Division of RI Application, Korea Institute of Radiological and Medical Sciences, 75 Nowon-Gil, Gongneung-Dong, Nowon-Gu, Seoul, 01812, Korea.
Sci Rep ; 11(1): 24397, 2021 12 22.
Article in English | MEDLINE | ID: covidwho-1585779
ABSTRACT
Angiotensin-converting enzyme 2 (ACE2) is an important factor in coronavirus disease (COVID-19) interactions. Losartan (LOS) belongs to the angiotensin receptor blocker (ARB) family. Additionally, the protective role of ACE2 restored by LOS has been suggested and clinically examined in the treatment of COVID-19 patients. Furthermore, clinical trials with LOS have been conducted. However, the mechanism through which LOS enhances ACE2 expression remains unclear. In addition, the response of ACE2 to LOS differs among patients. Our LOS-treated patient data revealed a correlated mechanism of ACE2 with components of the renin-angiotensinogen system. We observed a significant positive regulation of MAS1 and ACE2 expression. In the context of LOS treatment of COVID-19, ACE2 expression could depend on LOS regulated MAS1. Thus, MAS1 expression could predict the COVID-19 treatment response of LOS.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Renin-Angiotensin System / Losartan / Angiotensin Receptor Antagonists / Angiotensin-Converting Enzyme 2 Type of study: Prognostic study Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Renin-Angiotensin System / Losartan / Angiotensin Receptor Antagonists / Angiotensin-Converting Enzyme 2 Type of study: Prognostic study Limits: Humans Language: English Journal: Sci Rep Year: 2021 Document Type: Article